CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

Recruiting now · Phase 2

Conditions studied: B-cell Non Hodgkin Lymphoma

In brief

Clinical trial for the safety and efficacy of CD19 CAR-T following autologous hematopoietic stem cell transplantation (ASCT) for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) with High-Risk Prognostic Factors

Key facts

Study ID

NCT06365671

Run by

Ruijin Hospital

People needed

16

Starts

2024-04-16

Expected to finish

2027-04-01

Last updated by the study team

2026-01-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed B-cell non-Hodgkin's lymphoma including the following types
• diffuse large B-cell lymphoma
• high-grade B-cell lymphoma with or without MYC and BLC2 and/or BCL6 rearrangement
• transformed lymphoma
• primary mediastinal large B-cell lymphoma
• follicular lymphoma (FL)
• Relapsed or refractory diseases fulfilling one of the following criteria (individuals must have received anti-CD20 monoclonal antibody and anthracycline-containing chemotherapy regimen)
• Primary refractory disease, defined as disease progression after first-line immunochemotherapy or disease progression within 6 weeks of the end of the last chemotherapy
• Stable disease (SD) as best response after at least 4 cycles of first-line therapy
• Partial response (PR) as best response after at least 6 cycles of first-line therapy (biopsy-proven residual disease is needed for individuals with Deauville score of 4)
• PR as best response after at least 2 cycles of second-line therapy
• Disease relapse ≤12 months after the completion of first-line immunochemotherapy
• Relapsed or refractory disease after ≥2 lines of chemotherapy
• Presence of at least one of the following high-risk prognostic factors: (1) extranodal involvement; (2) maximum diameter of the bulky mass ≥5 cm; (3) TP53 gene alterations
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• Eligible for HDCT/ASCT based on the investigator's assessment and are scheduled to undergo an ASCT sequential CAR-T treatment regimen
• Adequate renal and hepatic function defined as:
• Serum alanine aminotransferase (ALT/AST) ≤ 3 upper limit of normal (ULN)
• Total bilirubin ≤1.5 mg/dL(<3 times ULN in patients with Gilbert's syndrome, cholestasis due to hepatoportal compression adenopathy, biliary obstruction in patients with liver involvement or lymphoma)
• Serum creatinine ≤1.5 ULN, or creatinine clearance (as estimated by Cockcroft Gault) ≥ 30 mL/min
• Cardiac ejection fraction ≥ 40%
• Baseline oxygen saturation > 95% on room air
• Life expectancy ≥3 months

You may not qualify if…

• History of autologous or allogeneic stem cell transplantation
• Active HBV or HCV infection, defined as HBV-DNA or HCV-DNA levels above the normal upper limit, with or without abnormal liver function. Individuals with positive HBsAg or HBcAb should receive antiviral prophylaxis for at least 12 months after CAR-T cells infusion.
• Presence of uncontrolled infection, cardio-cerebrovascular disease，coagulopathy, or connective tissue disease.
• History of HIV infection
• Prior chimeric antigen receptor cellular immunotherapy targeting CD19
• Pregnant or lactating patients

Where it is running

• Ruijin Hospital, Shanghai Jiao Tong University School of Medicine — Shanghai, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.